- Clovis Oncology Inc CLVS shares declined 14 percent to $30.77 after the company disclosed its oral presentation of the primary efficacy and safety data for rucaparib from its NDA dataset at the 2016 ESMO Congress. The company indicated that the drug candidate is under FDA's priority review for the treatment of monotherapy of advanced ovarian cancer in patients with BRCA-mutated tumors inclusive of germline and somatic BRCA mutations. The submission date for PDUFA is February 23, 2017.
- Idera Pharmaceuticals Inc IDRA shares dropped 13.3 percent to $1.89 after dropping 16.48 percent on Thursday.
- Biostage Inc BSTG shares declined 12.7 percent to $0.961 after the company issued a regulatory update on Cellspan Esophageal Implant.
- Aurinia Pharmaceuticals Inc AUPH shares dropped 12.4 percent to $4.47 after surging 25.93 percent on Thursday.
- Mistras Group Inc MG shares declined 11.7 percent to $20.59 after the company reported weak revenue for the first quarter and cut its fiscal 2017 outlook.
- Ruby Tuesday, Inc. RT shares fell 11 percent to $2.23 as the company posted a wider-than-expected loss for its first quarter on Thursday.
- Solaredge Technologies Inc SEDG shares declined 9.5 percent to $15.59. Goldman Sachs downgraded SolarEdge Technologies from Neutral to Sell and lowered the price target from $19.00 to $12.00.
- H&E Equipment Services, Inc. HEES fell 9.3 percent to $15.80. UBS downgraded H&E Equipment to Sell.
- Coupa Software Inc COUP shares dropped 9.1 percent to $30.24 after gaining 84.89 percent on Thursday.
- Tyson Foods, Inc. TSN shares fell 8.8 percent to $67.85. Pivotal Research downgraded Tyson from Buy to Sell.
- Honeywell International Inc. HON shares declined 8.6 percent to $105.68 after the company cut the upper end of its sales and earnings guidance range for 2016.
- Merrimack Pharmaceuticals Inc MACK fell 7.4 percent to $5.54. JP Morgan downgraded Merrimack Pharmaceuticals from Overweight to Neutral.
- Acacia Communications, Inc. ACIA shares dropped 6.7 percent to $102.07. Acacia Communications priced its 4.5 million share offering at $100 per share.
- First Solar, Inc. FSLR shares fell 5.5 percent to $37.55. Goldman Sachs downgraded First Solar from Buy to Neutral and lowered the price target from $58.00 to $42.00.
- Helen of Troy Limited HELE shares dropped 5.4 percent to $82.16. Helen of Troy reported stronger-than-expected results for its second quarter on Thursday.
- Alnylam Pharmaceuticals, Inc. ALNY shares fell 4.9 percent to $34.45. Morgan Stanley downgraded Alnylam Pharmaceuticals from Overweight to Equal-weight.
- Exelixis, Inc. EXEL fell 3.4 percent to $12.73 after the company disclosed Phase 1 trial results for cabozantinib in combination with nivolumab in advanced genitourinary tumors.
- Actuant Corporation ATU dropped around 3 percent to $23.29. Wells Fargo downgraded Actuant from Outperform to Market Perform.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
